Project description
|
Consortium members
|
Research priority area
|
Regional location
|
Total DTIF award (in principle)
|
VascuSense is a non-invasive device that will treat patients with chronic total occlusion, or complete blockages of coronary arteries that lead to critical limb ischemia. |
1) Versono Medical Ltd (LEAD), 2) Integer Ireland Medical Ltd, 3) National University of Ireland, Galway (NUIG), 4) Technology University Dublin (TUD) |
Health & Wellbeing |
Galway |
€7 million |
Heallntel will capture multifaceted data to enable data-driven improvements to products and protocols associated with measuring and monitoring compression therapy and wound care. |
1) FeelTect Ltd (LEAD), 2) Armour Interactive Ltd, 3) Odyssey Validation Consultants Ltd, 4) National University of Ireland, Galway (NUIG) |
Health & Wellbeing |
Galway |
€4.6 million |
LILAC-IntelliSense is a software system that models a prognosis for Chemotherapy Induced Peripheral Neuropathy (CIPN) based on clinically obtained observations and smart bioinformatics algorithms, improving treatment outcomes while reducing long-term side effects. |
1) Luminate Medical Ltd (LEAD), 2) Gentian Consultancy Services Ltd, 3) National University of Ireland Galway (NUIG), 4) Trinity College Dublin (TCD) |
Health & Wellbeing |
Galway |
€4.4 million |
Xbat+ will disrupt the global recycling market by identifying the potential hazards and risks associated with the Waste Electrical and Electronic Equipment (WEEE) recycling sector. |
1) University of Limerick (LEAD), 2) Peregrine Technologies (Holdings) Ltd, 3) Somex Automation Teoranta, 4) Helgen Technologies Ltd |
Energy, Climate Action and Sustainability |
Limerick |
€3.7 million |
Ceroflo, Advant Medical and Galway-Mayo Institute of Technology (GMIT) will develop a DB stent that is more effective and efficient but will also eliminate pre-stent procedures and mitigate risks associated with conventional stent procedures. |
1) Ceroflo Ltd (LEAD), 2) Advant Medical Ltd, 3) Galway Mayo Institute of Technology (GMIT) |
Health & Wellbeing |
Dublin |
€3.6 million |
BioBlate will disrupt the current treatment of Diabetic Foot Ulcers and other mixed tissue infections by developing a non-invasive surgical device that delivers a high amplitude of electrical pulses to remove infected muscle and bone tissues, preserving the integrity of the wound bed to promote healing. |
1) Xtremedy Medical Ltd (LEAD), 2) Design Partners Ltd, 3) National University of Ireland, Galway (NUIG) |
Health & Wellbeing |
Galway |
€3.4 million |
This consortium seeks to develop Thorax: an AI-driven patient monitoring platform, combined with a diagnostic test capable of identifying patients at high risk of progression of acute diseases (sepsis/pneumonia). |
1) Novus Diagnostics Ltd (LEAD), 2) Dolmen Design and Innovation Ltd, 3) National University of Ireland, Dublin (UCD), 4) Royal College of Surgeons in Ireland (RCSI) |
Health & Wellbeing |
Dublin |
€3.3 million |
This project will develop a miniature implantable smart pump for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) which limits the need for open-heart surgery. |
1) Pumpinheart Ltd (LEAD), 2) Gentian Consultancy Services Ltd, 3) Boston Scientific Ltd, 4) Royal College of Surgeons in Ireland, RCSI |
Health & Wellbeing |
Dublin |
€3.1 million |
Cilter is an AI-driven parental control concept that will modify a phone at the kernel level to access all incoming and outgoing data and encrypt messaging apps. |
1) Cilter Technologies Ltd (LEAD), 2) O'Neill Amarach Consultants Ltd, 3) Dublin City University |
ICT |
Dublin |
€2.8 million |
EncOVac will develop an orally self-administered vaccine technology delivered to intestinal mucosa to better protect against pathogens. |
1) Poolbeg Pharma (Ireland) Ltd (LEAD), 2) Anabio Technologies UnLtd Company, 3) Trinity College Dublin (TCD), 4) National University of Ireland, Dublin (UCD) |
Health & Wellbeing |
Dublin |
€2.3 million |
RISOLVE proposes the developmentof a safe and effective personalised therapy that will disrupt the Overactive Bladder Treatment market using an innovative artificial intelligence-based digital platform. |
1) Amara Therapeutics Ltd (LEAD), 2) TEKenable Ltd, 3) National University of Ireland Galway (NUIG) |
ICT |
Dublin |
€1.5 million |